AXL and non-small cell lung carcinoma: Similarly, early data from a phase I/II trial investigating bemcentinib (BGB324) with the PD-1 blocker pembrolizumab in resistant non-small cell lung cancer showed a 24% response rate, rising to 40% in AXL positive patients, with manageable toxicity, underscoring both the potential for efficacy in general and the value of AXL expression as a predictive marker [58].